Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Long-term Role of Pioglitazone in Non-Alcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes Mellitus (T2DM).
Brief Summary: Obesity and Type 2 diabetes are creating a silent epidemic, Non-alcoholic fatty liver disease, which is a chronic liver disease associated with insulin resistance, impaired glucose intolerance, and hepatic fat accumulation. The thiazolidinedione pioglitazone improves glucose/lipid metabolism and histology in NASH by improving insulin resistance in the liver/peripheral/adipose tissues and reducing subclinical inflammation. The aim of this study is to assess the underlying mechanisms at the clinical and molecular level and the long-term efficacy and safety of pioglitazone in NASH in a multiethnic cohort of subjects (predominantly Hispanics, Caucasians and African-Americans - the most common ethnic groups locally) and examine the response including patients with normal glucose tolerance, impaired glucose tolerance or established type 2 diabetes mellitus (T2DM).


Options:
A: Arm Label: Pioglitazone; Type: EXPERIMENTAL; Interventions: Drug: Pioglitazone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Pioglitazone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68); Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68); Type: EXPERIMENTAL; Interventions: Drug: placebo | Arm Label: Liraglutide Placebo, no Pre-diabetes; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Liraglutide 3.0mg, Pre-diabetes; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Liraglutide Placebo, Pre-diabetes; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68) | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68), Liraglutide Placebo, no Pre-diabetes | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide 3.0mg, Pre-diabetes | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Liraglutide Placebo, Pre-diabetes
C: Arm Label: Pioglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pioglitazone study drug, Drug: Pioglitazone Open Label | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Pioglitazone Open Label | Intervention Type: DRUG; Name: Pioglitazone study drug; Assigned to Arm(s): Pioglitazone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Pioglitazone Open Label; Assigned to Arm(s): Pioglitazone, Placebo
D: Arm Label: Pioglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: pioglitazone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): Pioglitazone | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: C